In a new Yale-led study, investigators have revealed previously unknown factors that contribute to the hardening of arteries and plaque growth, which cause heart disease. Their insight is the basis for a promising therapeutic approach to halt and potentially reverse plaque buildup and the progression of disease, the researchers said.
Current treatments for plaque and hardened arteries, a condition known as atherosclerosis, can slow but not improve the disease. Experts believe that may be due to ongoing inflammation in blood vessels. To understand the factors contributing to this inflammation, the research team focused on a group of proteins, called transforming growth factor beta (TGFß), that regulates a wide range of cells and tissues throughout the body.
Using cultured human cells, the researchers discovered that TGF? proteins trigger inflammation in endothelial cells — the cells that form the inner lining of artery walls — but not in other cell types. With a technique called single cell RNA-seq analysis, which measures the expression of every gene in single cells, they then showed that TGF? induced inflammation in these cells in mouse models. This finding was notable, said the researchers, because TGF? proteins are known to decrease inflammation in other cells in the body.
The researchers also showed that when the TGF? receptor gene is deleted in endothelial cells, both the inflammation and plaque in blood vessels are significantly reduced.
To test this approach as a potential therapy, the team, led by professor of medicine Michael Simons, M.D., used an “interfering” RNA, or RNAi, drug developed at Yale, to disrupt TGFß receptors. Interfering RNA use a gene’s own DNA sequence to turn off or silence the gene. To deliver the drug only to endothelial cells in the blood vessel walls of mice, they employed microscopic particles, or nanoparticles, created by their co-authors at MIT. This strategy reduced inflammation and plaque as effectively as the genetic technique.
The findings identify TGFß signaling as a major cause of chronic vessel wall inflammation, and demonstrate that disruption of this pathway leads to cessation of inflammation and substantial regression of existing plaque, said the scientists.
Based on this discovery, investigators at Yale and MIT have launched a biotech company, VasoRX, Inc., to develop this targeted approach, using the RNAi drug delivered by nanoparticles as a potential therapy for atherosclerosis in people.
The Latest on: Atherosclerosis
via Google News
The Latest on: Atherosclerosis
- PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cellson November 14, 2019 at 3:06 am
Endothelial pro-inflammatory activation plays a pivotal role in atherosclerosis, and many pro-inflammatory and atherogenic signals converge upon mechanistic target of rapamycin (mTOR). Inhibitors of ...
- MemorialCare Orange Coast Medical Center Offers TCAR Procedureon November 13, 2019 at 5:46 pm
TCAR is a clinically proven, minimally invasive and safe approach for high surgical risk patients who need carotid artery treatment. Carotid artery disease is a form of atherosclerosis, or a buildup ...
- The Latest Weight Loss Pills That Work—And the Ones That Don'ton November 11, 2019 at 2:30 pm
M.D., F.O.M.A., F.T.O.S., F.A.C.C., F.A.C.E., F.N.L.A., medical director and president of Louisville Metabolic and Atherosclerosis Research Center and chief science officer for the Obesity Medical ...
- Cholesterol Screening/ Cholesterol Lab Testing Services Market Size, Growth, Opportunity and Forecast to 2025on November 11, 2019 at 12:48 am
Low-density lipoprotein (LDL) cholesterol is referred to as bad cholesterol. High amount of bad cholesterol raises risk of heart attack, stroke, and atherosclerosis. Download Sample of This Strategic ...
- CohBar - The Pioneer In Mitochondrial Drugson November 9, 2019 at 5:23 am
CohBar (CWBR) is a development-stage biotech company focused on drugs based on mitochondria-based therapeutics (MBTs), an emerging class of drugs with the potential to treat a wide range of diseases ...
- Platelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosison November 6, 2019 at 11:39 am
Marc and Ruti Bell Program in Vascular Biology, Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
- Atherosclerosis: Scientists identify new protein target in immune cellson November 1, 2019 at 12:05 pm
Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a current ...
- Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosison October 22, 2019 at 6:23 am
Atherosclerosis is a disease in which plaque build-up results in thickening and hardening of the walls of the arteries. These structural changes can lead to a reduction of blood flow to the brain and ...
- 'Good' cholesterol counters atherosclerosis in mice with diabeteson September 29, 2019 at 5:00 pm
Increasing levels of a simplified version of 'good' cholesterol reversed disease in the blood vessels of mice with diabetes. Published online in the journal Circulation on September 30, the study ...
- Mummies show atherosclerosis was prevalent in ancient timeson September 24, 2019 at 2:16 pm
They are thought to be from the period 2000 BC to 1000 AD. The study looked for any evidence that these people had suffered arterial damage due to atherosclerosis. This is a term that refers to the ...
via Bing News